Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026)
Precigen (PGEN) reported Total Non-Current Liabilities of $118.3 million for Q1 2026, up 290.24% year-over-year from $30.3 million in Q1 2025, and down 12.03% quarter-over-quarter from $134.5 million in Q4 2025.
Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Total Non-Current Liabilities data on file, last reported at $118.3 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $118.3 million, up 290.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.3 million (up 290.24% YoY), and the FY2025 annual result was $134.5 million, up 71.21% from the prior year.
- Total Non-Current Liabilities slipped to $118.3 million in Q1 2026 per PGEN's latest filing, from $134.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $261.7 million in Q1 2022 and troughed at $29.2 million in Q2 2025.
- A 5-year average of $101.8 million and a median of $98.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities increased 12.75% in 2022, then surged 290.24% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $261.7 million in 2022, then sank by 87.56% to $32.5 million in 2023, then soared by 141.31% to $78.5 million in 2024, then surged by 71.21% to $134.5 million in 2025, then slipped by 12.03% to $118.3 million in 2026.
- Business Quant data shows PGEN's Total Non-Current Liabilities at $118.3 million in Q1 2026, $134.5 million in Q4 2025, and $129.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | 118.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.29 Mn |
| Dec 31, 2025 | 134.46 Mn |
| Sep 30, 2025 | 129.23 Mn |
| Jun 30, 2025 | 29.23 Mn |
| Mar 31, 2025 | 30.31 Mn |
| Dec 31, 2024 | 78.54 Mn |
| Dec 31, 2023 | 32.55 Mn |
| Mar 31, 2022 | 261.68 Mn |
| Dec 31, 2021 | 252.46 Mn |
| Sep 30, 2021 | 245.60 Mn |
| Jun 30, 2021 | 243.33 Mn |
| Mar 31, 2021 | 232.09 Mn |
| Dec 31, 2020 | 247.31 Mn |
| Sep 30, 2020 | 277.53 Mn |
| Jun 30, 2020 | 312.07 Mn |
| Dec 31, 2019 | 88,000.00 |
| Sep 30, 2019 | 376.26 Mn |
| Jun 30, 2019 | 375.74 Mn |
| Mar 31, 2019 | 374.38 Mn |
| Dec 31, 2018 | 334.32 Mn |